Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $77 | $94 | $77 | $67 |
| - Cash | $2 | $3 | $3 | $3 |
| + Debt | $3 | $3 | $3 | $3 |
| Enterprise Value | $77 | $94 | $77 | $67 |
| Revenue | $14 | $13 | $12 | $16 |
| % Growth | 8.3% | 7.8% | -24.3% | – |
| Gross Profit | $12 | $11 | $10 | $13 |
| % Margin | 86.1% | 82.9% | 86% | 83.1% |
| EBITDA | $5 | $5 | $5 | $10 |
| % Margin | 37.4% | 35.8% | 43.2% | 60.2% |
| Net Income | $4 | $4 | $4 | $8 |
| % Margin | 31.1% | 30.1% | 35.6% | 50.2% |
| EPS Diluted | 38.34 | 34.77 | 38.22 | 71.97 |
| % Growth | 10.3% | -9% | -46.9% | – |
| Operating Cash Flow | $4 | $5 | $5 | $7 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | $4 | $4 | $4 | $7 |